Condition: Lysosomal Storage Disorders · Sandhoff Disease · Krabbe Disease · Sponsor: Polaryx Therapeutics, Inc.
The purpose of this study is to evaluate the safety, tolerability and clinical activity of PLX-200 in pediatric patients with lysosomal storage disorders.
This description comes directly from the study's public registry record.
Minsu Kang, PhD · 217-779-7736 · minsukang@polaryx.com
Always discuss trial participation with your own doctor first.
| Locations not yet listed on the registry record. |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07740512